Transurethral enzyme injection--future management of benign prostatic hyperplasia.
Although benign prostatic hyperplasia, a common condition among elderly men, has been effectively treated with transurethral resection of the prostate, this surgical procedure is associated with many well-recognized risks and complications. Because of this potential morbidity and mortality, various alternative treatment strategies for benign prostatic hyperplasia have been proposed. The use of enzyme solubilization and ablation of prostatic tissue to alleviate urinary outlet obstruction has proved effective in dogs and warrants investigation in human trials. Transurethral enzyme injection of the prostate has the potential for being a treatment modality with minimal invasiveness, limited requirements for anesthesia, and minimal associated toxicity for the management of benign prostatic hyperplasia.
Darson
M F
MF
Department of Urology, Mayo Clinic Rochester, Minnesota 55905, USA.
Barrett
D M
DM
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017364:Collagenases / Q000008:administration & dosage / Q000627:therapeutic use*; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage / Q000627:therapeutic use*; D007267:Injections / Q000379:methods; D008297:Male; D017830:Octoxynol / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013501:Surface-Active Agents / Q000627:therapeutic use; D016896:Treatment Outcome; D014521:Urethra
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D013501:Surface-Active Agents; D017830:Octoxynol; D006821:Hyaluronoglucosaminidase; D017364:Collagenases